Comparative Pharmacology
Head-to-head clinical analysis: CATAPRES TTS 1 versus CATAPRES TTS 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAPRES TTS 1 versus CATAPRES TTS 2.
CATAPRES-TTS-1 vs CATAPRES-TTS-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic agonist that reduces sympathetic outflow from the CNS, leading to decreased peripheral vascular resistance and blood pressure.
Clonidine is a centrally acting alpha-2 adrenergic agonist that stimulates alpha-2 adrenergic receptors in the brainstem, activating inhibitory neurons and reducing sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance, heart rate, and blood pressure.
Clonidine transdermal system 0.1 mg/24 hours applied to intact skin on upper arm or chest once every 7 days. Titrate based on response, maximum 0.3 mg/24 hours.
Transdermal patch delivering 0.2 mg/day clonidine applied every 7 days to hairless area of upper arm or chest.
None Documented
None Documented
12-16 hours; may be prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life: 12–16 hours (up to 48 hours following transdermal administration due to continued absorption from the skin depot).
Renal: 40-60% unchanged; biliary/fecal: ~20% as metabolites; remainder metabolized.
Renal: ~65% as unchanged drug; biliary/fecal: ~20% as metabolites; about 15% eliminated as metabolites in urine.
Category C
Category C
Central Alpha-Agonist
Central Alpha-Agonist